“I love working with entrepreneurs at the earliest stage of science.  When success comes from these very novel ideas, you can truly revolutionize health care for patients.”

Kendall M. Mohler, PhD


Kendall M. Mohler, Ph.D., serves as Managing Director and Chief Development Officer of Accelerator. With more than three decades of biopharmaceutical industry experience, Ken has lead scientific research and development teams in autoimmune disease, inflammation, and oncology. He provides Accelerator teams oversight over scientific research and product development.

Ken served as Senior Vice President of Research at Juno Therapeutics Inc. (NASDAQ: JUNO), a clinical-stage cell immunotherapy company focused on re-engaging the body’s immune system to treat cancer. Before that, he served as Chief Scientific Officer of Juno Therapeutics Inc. and ZetaRx Biosciences, Inc., a predecessor company acquired by Juno.

Before Juno, Ken co-founded Trubion Pharmaceuticals Inc. (NASDAQ: TRBN), a biopharmaceutical company focused on developing novel protein therapeutics to treat autoimmune and inflammatory diseases and cancer. At Trubion, Ken served as the Company’s Chief Scientific Officer and Senior Vice President, overseeing several first-in-class product candidates and supporting several partnerships with global pharmaceutical companies.

Prior to Trubion, Ken served as Vice President of Biological Sciences of Immunex Corporation (NASDAQ: IMNX), where he led research and development activities in the areas of transplantation, autoimmunity, and inflammation. He was the preclinical lead for Enbrel’s research and development activities and successfully shepherded the product from inception through BLA approval. Ken also serves on the Board of Neuvogen, an immunoncology company based in San Diego, CA.

He received a Ph.D. in Immunology from the University of Texas Health Science Center and a B.S. from the University of Kansas.